[1] Seute T, Leffers P, ten Velde GP, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma[J]. Cancer, 2004, 100:801-806.
[2] Goncalves PH, Peterson SL, Vigneau FD, Shore RD, Quarshie WO, Islam K, Schwartz AG, Wozniak AJ, Gadgeel SM. Risk of brain metastases in patients with nonmetastatic lung cancer:Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data[J]. Cancer, 2016, 122:1921-1927.
[3] Machie TR, Holmes T, Swerdloff S, Reckwerdt P, Deasy JO, Yang J, Paliwal B, Kinsella T. Tomotherapy:a new concept for the delivery of dynamic conformal radiotherapy[J]. Med Phys, 1993, 20:1709-1719.
[4] Ma YC, Xiao JP, Bi N, Xu YJ, Tian Y, Zhang HM, Zhang Y, Liu QF, Deng L, Wang WQ, Zhao RZ, Yang SR, Yi JL, Li YX. Whole-brain irradiation with simultaneous integrated boost by helical tomotherapy for multiple brain metastases:dosimetric and clinical analyses[J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 2018, 27:435-440.[马玉超,肖建平,毕楠,徐英杰,田源,张红梅,张烨,刘清峰,邓垒,王文卿,赵瑞芝,杨斯苒,易俊林,李晔雄. HT全脑+病灶同步推量放疗多发性脑转移瘤剂量学及临床分析[J].中华放射肿瘤学杂志, 2018, 27:435-440.]
[5] van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ. Survival of human glioma cells treated with various combination of temozolomide and X-rays[J]. Int J Radiat Oncol Biol Phys, 2000, 47:779-784.
[6] Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme[J]. Clin Adv Hematol Oncol, 2007, 5:894-902.
[7] van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ, Sminia P. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines[J]. Int J Radiat Oncol Biol Phys, 2007, 69:1246-1253.
[8] NCCN clinical practice guidelines in oncology:small cell lung cancer[DB/OL]. 2018[2019-10-10]. http://nccn.org.
[9] Ma W, Li N, An Y, Zhou C, Bo C, Zhang G. Effects of temozolomide and radiotherapy on brain metastatic tumor:a systematic review and Meta-analysis[J]. World Neurosurg, 2016, 92:197-205.
[10] Bi N, Ma Y, Xiao J, Zhang H, Xu Y, Tian Y, Li J, Zhang Y, Liu Q, Wang K, Deng L, Wang W, Chen X, Liu F, Zhao R, Yang S, Huang X, Yi J, Hu C, Li Y. A phase Ⅱ trial of concurrent temozolomide and hypofractionated stereotactic radiotherapy for complex brain metastases[J]. Oncologist, 2019, 24:E914-920.
[11] Ma YC, Xiao JP, Bi N, Zhang HM, Xu YJ, Zhang Y, Liu QF, Deng L, Wang WQ, Liu F, Wang K, Zhao RZ, Yang SR, Yi JL, Li YX. Case-control study of fractionated stereotactic radiotherapy combined with temozolomide for large brain metastases[J]. Zhonghua Fang She Zhong Liu Xue Za Zhi, 2018, 27:348-353.[马玉超,肖建平,毕楠,张红梅,徐英杰,张烨,刘清峰,邓垒,王文卿,刘峰,王凯,赵瑞芝,杨斯苒,易俊林,李晔雄. FSRT联合替莫唑胺治疗大体积脑转移瘤的对照研究[J].中华放射肿瘤学杂志, 2018, 27:348-353.]
[12] Wu X, Li JL, Xiao JP, Yang BY, Yu L, Wu XM, Wan JH, Xu HY, Kong JX. Efficacy and security of intrathecal with methotrexate in the treatment of meningeal carcinomatosis[J]. Zhongguo Fei Ai Za Zhi, 2016, 19:252-256.[吴熙,李俊岭,肖建平,杨渤彦,于雷,吴晓明,万经海,徐海燕,孔建新.甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察[J].中国肺癌杂志, 2016, 19:252-256.]
[13] Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, Boulanger T, Peters S, Watts C, Wick W, Wesseling P, Rudà R, Preusser M; EANO Executive Board and ESMO Guidelines Committee. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours[J]. Ann Oncol, 2017, 28(Suppl 4):84-99. |